研究

Takamori S, Endo M, Hamada A, Ohara S, Fukuda S, Tomioka Y, Takamori S, Osoegawa A, Nomura K, Fujino K, Yoshikawa M, Suzawa K, Shien K, Suda K, Kinoshita F, Hayasaka K, Notsuda H, Nagano T, Matsudo K, Hashinokuchi A, Matsubara T, Katsumata S, Shiono S, Soh J, Ohde Y, Shimokawa M.

Prognostic Analysis of Pathological Stage I Lung Adenocarcinoma Harboring Major EGFR Mutations

Sakai K, Ohara S, Tanaka J, Suda K, Muramatsu T, Uematsu C, Tsutani Y, Mitsudomi T, Nishio K

Improved platelet separation performance from whole blood using an acoustic fluidics system

Ujiie H, Ebana H, Suzuki J, Chiba M, Watanabe H, Kobayashi A, Shiono S, Tsutani Y, Kato T.

Developing novel non-assistant help operation in dual-portal robotic-assisted thoracic surgery (neoDRATS)

Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, Forde PM, Higgins KA, Kris MG, Mitsudomi T, Provencio M, Senan S, Solomon BJ, Tsao MS, Tsuboi M, Wakelee HA, Wu YL, Chih-Hsin Yang J, Zhou C, Harpole DH, Kelly KL.

Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer

Ohara S, Suda K, Hamada A, Chiba M, Ito M, Shimoji M, Takemoto T, Soh J, Tsutani Y

Clinical factors associated with high PD-L1 expression in patients with early-stage non-small cell lung cancer

Hayashi H, Nishio M, Akamatsu H, Goto Y, Miura S, Gemma A, Yoshino I, Misumi T, Kijima T, Takase N, Fujita M, Tasaka S, Mouri A, Kondo T, Takamura K, Kawashima Y, Imaizumi K, Iwasawa S, Nakagawa S, Mitsudomi T.

Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer

Tetsuya Mitsudomi

Savolitinib in NSCLC: progress in the MET exon 14 journey

Akamatsu H, Koh Y, Nishio M, Goto Y, Hayashi H, Miura S, Tamada K, Kagamu H, Gemma A, Yoshino I, Misumi T, Mouri A, Saito R, Takase N, Yanagitani N, Nokihara H, Seike M, Takamura K, Mori M, Iwasawa S, Nakagawa S, Mitsudomi T.

Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer

Kamigaichi A, Hamada A, Tsuboi M, Yoshimura K, Okamoto I, Yamamoto N, Tsutani Y.

A Multi-Institutional, Randomized, Phase III Trial Comparing Anatomical Segmentectomy and Lobectomy for Clinical Stage IA3 Pure-Solid Non-Small-Cell Lung Cancer: West Japan Oncology Group Study WJOG16923L (STEP UP Trial)

Tetsuya Mitsudomi, Hiroyuki Ito, Morihito Okada, Shunichi Sugawara, Yutaka Shio, Keisuke Tomii, Jiro Okami, Noriaki Sakakura, Kaoru Kubota, Kazuya Takamochi, Shinji Atagi, Masahiro Tsuboi, Satoshi Oizumi, Norihiko Ikeda, Yasuhisa Ohde, Ives Ntambwe, Javed Mahmood, Junliang Cai, Fumihiro Tanaka

Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 817

Satoshi Ikeda, Masahiro Tsuboi, Kazuko Sakai, Toshihiro Misumi, Hiroaki Akamatsu, Hiroyasu Shoda, Noriaki Sakakura, Atsushi Nakamura, Yasuhisa Ohde, Hidetoshi Hayashi, Kyoichi Okishio, Morihito Okada, Ichiro Yoshino, Jiro Okami, Kazuhisa Takahashi, Norihiko Ikeda, Masayuki Tanahashi, Yuichi Tambo, Haruhiro Saito, Shinichi Toyooka, Hidetoshi Inokawa, Toyofumi Chen-Yoshikawa, Toshihide Yokoyama, Tatsuro Okamoto, Noriko Yanagitani, Masahide Oki, Makoto Takahama, Kenji Sawa, Hirohito Tada, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Kazuto Nishio

NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study

Shimizu R, Suda K, Takemoto T, Fukuda S, Chiba M, Shimoji M, Soh J, Mitsudomi T, Tsutani Y.

A case of late-onset bleeding from an intercostal artery pseudoaneurysm after hemostasis using soft coagulation.

Haratake N, Ozawa H, Morimoto Y, Yamashita N, Daimon T, Bhattacharya A, Wang K, Nakashoji A, Isozaki H, Shimokawa M, Kikutake C, Suyama M, Hashinokuchi A, Takada K, Takenaka T, Yoshizumi T, Mitsudomi T, Hata AN, Kufe D.

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC

Katsumata S, Shimokawa M, Hamada A, Haratake N, Nomura K, Fujino K, Yoshikawa M, Suzawa K, Shien K, Suda K, Ohara S, Fukuda S, Kinoshita F, Hayasaka K, Notsuda H, Takamori S, Muto S, Takanashi Y, Mizuno K, Kawase A, Hayakawa T, Sekihara K, Toda M, Matsuo S, Takegahara K, Hashimoto M, Nakahashi K, Endo M, Ozawa H, Fujikawa R, Tomioka Y, Namba K, Matsubara T, Suzuki J, Watanabe H, Takada K, Hoshino H, Kaiho T, Toyoda T, Kouki Y, Shiono S, Soh J, Ohde Y.

Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study

Izaki Y, Mimae T, Kagimoto A, Handa Y, Tsutani Y, Miyata Y, Okada M, Takeshima Y.

Differences in postoperative prognosis between early-stage lung adenocarcinoma and squamous cell carcinoma.

Chen X, Zhou H, Wu M, Xu M, Li T, Wang J, Sun X, Tsutani Y, Xie M.

Prognostic impact of spread through air spaces in patients with ≤2 cm stage IA lung adenocarcinoma.

Rosell R, Jantus-Lewintre E, Cao P, Cai X, Xing B, Ito M, Gomez-Vazquez JL, Marco-Jordán M, Calabuig-Fariñas S, Cardona AF, Codony-Servat J, Gonzalez J, València-Clua K, Aguilar A, Pedraz-Valdunciel C, Dantes Z, Jain A, Chandan S, Molina-Vila MA, Arrieta O, Ferrero M, Camps C, González-Cao M.

KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.

Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, Forde PM, Higgins KA, Kris MG, Mitsudomi T, Provencio M, Senan S, Solomon BJ, Tsao MS, Tsuboi M, Wakelee HA, Wu YL, Chih-Hsin Yang J, Zhou C, Harpole DH, Kelly KL.

Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer.

Shota Fukuda, Kenichi Suda, Akira Hamada, Hana Oiki, Shuta Ohara, Masaoki Ito, Junichi Soh, Tetsuya Mitsudomi, Yasuhiro Tsutani

Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms-An In Vitro Study

Tsutani Y, Miyata Y, Suzuki K, Tanaka F, Ito H, Yamashita Y, Okada M.

Pathologic Response and Survival after Neoadjuvant Chemotherapy with Bevacizumab Followed by Surgery for Clinical Stage II/IIIA Nonsquamous Non-Small-Cell Lung Cancer: Results from a Phase II Feasibility Study (NAVAL)

Yagishita S, Goto Y, Nishio M, Akamatsu H, Hayashi H, Miura S, Tamada K, Kagamu H, Hamada A, Ohuchi M, Gemma A, Yoshino I, Misumi T, Hata A, Hara S, Kijima T, Masaki F, Iwasawa S, Nakagawa S, Tatsuno M, Mitsudomi T.

Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL

Ito M, Suda K, Tsutani, Y.

Genetic profile characterization of histological micropapillary and solid components in lung adenocarcinoma: A systematic review.

Nakagawa K, Yotsukura M, Mimae T, Hattori A, Miyoshi T, Isaka M, Endo M, Tsutani Y, Isaka T, Maniwa T, Nakajima R, Yoshioka H, Takei H, Aokage K, Watanabe SI.

The Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group: outstanding contribution and entering a new phase

Watanabe SI, Yotsukura M, Miyoshi T, Hattori A, Isaka T, Maniwa T, Isaka M, Yoshioka H, Endo M, Mimae T, Tsutani Y, Nakagawa K, Aokage K; Lung Cancer Surgical Study Group (LCSSG) of the Japan Clinical Oncology Group (JCOG).

Updated review of perioperative treatment for non-small-cell lung cancer in the new era of immune checkpoint inhibitors: past, present, and future

Oya Y, Imaizumi K, Mitsudomi T.

The next-generation KRAS inhibitors...What comes after sotorasib and adagrasib?

Stephen Lam, Murry W Wynes, Casey Connolly, Kazuto Ashizawa, Sukhinder Atkar-Khattra, Chandra P Belani, Domenic DiNatale, Claudia I Henschke, Bruno Hochhegger, Claudio Jacomelli, Małgorzata Jelitto, Artit Jirapatnakul, Karen L Kelly, Karthik Krishnan, Takeshi Kobayashi, Jacqueline Logan, Juliane Mattos, John Mayo, Annette McWilliams, Tetsuya Mitsudomi, Ugo Pastorino, Joanna Polańska, Witold Rzyman, Ricardo Sales Dos Santos, Giorgio V Scagliotti, Heather Wakelee, David F Yankelevitz, John K Field, James L Mulshine, Ricardo Avila

The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative

Hattori A, Suzuki K, Takamochi K, Wakabayashi M, Sekino Y, Tsutani Y, Nakajima R, Aokage K, Saji H, Tsuboi M, Okada M, Asamura H, Nakamura K, Fukuda H, Watanabe SI; Japan Clinical Oncology Group; West Japan Oncology Group.

Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial.

Kamigaichi A, Hamada A, Tsuboi M, Yoshimura K, Okamoto I, Yamamoto N, Tsutani Y.

A multi-institutional, randomized, phase III trial comparing anatomical segmentectomy and lobectomy for clinical stage IA3 pure-solid non-small cell lung cancer: West Japan Oncology Group Study WJOG16923L (STEP UP trial)